A pair of licensing deals today for BioNTech and Takeda provide further examples that antibody-drug conjugates (ADCs) are cementing their place as in the biopharma armamen
AstraZeneca has abandoned a phase 3 trial of its experimental immuno-oncology candidate monalizumab in head and neck cancer, after an interim analysis suggested it was unlikely to show a be
France’s Innate Pharma has gained rights to AstraZeneca's recently approved leukaemia drug Lumoxiti, in a deal that expands a collaboration that began more than three years ago.
The future for Innate Pharma and Bristol-Myers Squibb’s cancer immunotherapy lirilumab looks uncertain, with the French biotech saying there is “no obvious development path” after another t
Innate Pharma’s lirilumab – a cancer immunotherapy being developed in partnership with Bristol-Myers Squibb – has failed in a phase 2 blood cancer trial.
Japan’s Taisho Pharmaceutical looks like it could be heading into private ownership, thanks to a management buyout offer (MBO) that could value the company at almost $5 bi
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio